The PI3K/AKT/mTOR signaling pathway is frequently altered in endometrial cancer, therefore capivasertib + AZD5991 could represent an active and potent combination in this cancer type that currently lacks effective treatments. Here, PIK3CA is linked to endometrial cancer.